Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Age Related Macular Degeneration, Macular Degeneration, AMD
Interventions: HuCNS-SC cells; Drug
Lead sponsor: StemCells, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Palo Alto, California • New York, New York + 2 more

Conditions: Cystoid Macular Edema
Interventions: Standard Care, nepafenac; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypoxic-Ischemic Encephalopathy
Interventions: Optical Coherence Tomography; Device
Lead sponsor: Duke University; Other
Eligibility: Up to 20 Days
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Durham, North Carolina • Salt Lake City, Utah

Conditions: CYSTOID MACULAR EDEMA
Interventions: Ranibizumab,, Triamcinolone acetonide; Drug
Lead sponsor: Soll Eye; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Retinitis Pigmentosa
Interventions: CNTO 2476; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 3
States / cities: Miami, Florida • Southwest Portland, Oregon • Dallas, Texas

Conditions: Diabetes, Diabetic Retinopathy
Interventions: No intervention; Device
Lead sponsor: iHealthScreen Inc; Industry
Eligibility: 22 Years and older
Enrollment: 935 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Richmond Hill, New York

Conditions: Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration, Macular Degeneration
Interventions: GEM103, Aflibercept, Sham; Biological · Drug
Lead sponsor: Gemini Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 23
States / cities: Phoenix, Arizona • Campbell, California • Encino, California + 19 more

Conditions: Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
Interventions: Observational Study; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 80 Years
Enrollment: 293 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 7
States / cities: San Diego, California • San Francisco, California • Baltimore, Maryland + 4 more

Conditions: Diabetic Macular Edema
Interventions: nepafenac 0.1% drops, Nepafenac Vehicle; Drug · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Loma Linda, California • Palm Springs, California • Santa Barbara, California + 29 more

Conditions: Eye Diseases, Retinal Disease, Glaucoma, Optic Nerve Diseases
Interventions: Auto-aligned OCT; Device
Lead sponsor: Duke University; Other
Eligibility: 1 Month and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Geographic Atrophy, Macular Degeneration
Interventions: Avacincaptad Pegol, Sham; Drug
Lead sponsor: IVERIC bio, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 96
States / cities: Beverly Hills, California • Campbell, California • Fresno, California + 86 more

Conditions: Central Nervous System/Leptomeningeal Neoplasms
Interventions: 131I-omburtamab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Diabetic Retinopathy, Age-Related Macular Degeneration, Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions: Optical Coherence Tomography; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Irvine, California

Conditions: Retinitis Pigmentosa
Interventions: Vitamin A, Docosahexaenoic acid, Control fatty acid; Dietary Supplement
Lead sponsor: Carol Weigel DiFranco; NIH
Eligibility: 18 Years to 55 Years
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2002
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stickler Syndrome Type 1, Stickler Syndrome Type 2
Interventions: Prophylactic (non-invasive) Laser Retinopexy; Procedure
Lead sponsor: Helen Keller Eye Research Foundation; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 6
States / cities: Birmingham, Alabama • Boston, Massachusetts • Royal Oak, Michigan + 3 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Foscarnet sodium, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 4 more

Conditions: Mild Nonproliferative Diabetic Retinopathy, Moderate Nonproliferative Diabetic Retinopathy, Severe Nonproliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Not listed
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Hilo, Hawaii

Conditions: Age-Related Macular Degeneration
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epiretinal Membrane, Vitreomacular Traction
Interventions: using ILM forceps alone, Breaking and peeling with end-grasping forceps; Procedure
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 19 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Corneal Diseases, Retinal Diseases, Ocular Diseases
Interventions: 4D MIOCT integrated into a Zeiss Artevo 800; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Macular Edema
Interventions: Ranibizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 42
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 38 more

Conditions: Macular Degeneration, Age-Related Macular Degeneration
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 10 Years to 100 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Vitrectomy, Macular Pucker, Retinal Edema
Interventions: Dexamethasone Intracanalicular Insert, 0.4 mg, Prednisone acetate 1%; Drug
Lead sponsor: Kovach Eye Institute; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Elmhurst, Illinois

Conditions: Neovascular (Wet) Age-Related Macular Degeneration
Interventions: aflibercept, High-dose aflibercept; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 45
States / cities: Phoenix, Arizona • Sun City, Arizona • Encino, California + 42 more

Search by objective public record fields.

Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)

Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery

Bedside Optical Retinal Assessment of Hypoxic Ischemic Encephalopathy in Infants

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa

Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)

Advancing Pediatric Retinal Imaging With Auto-aligned OCT

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging

Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A

Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)

Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component

Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography

Investigating Age-Related Macular Degeneration

Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel

4D Duke Microscope Integrated Optical Coherence Tomography in a Zeiss Artevo 800

A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

The Focal Electro-Oculogram in Macular Disease

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration